and Launches Tender Offer for HISAMITSU PHARMACEUTICAL CO.,INC. at undisclosed

Source disclosure: February 03, 2026

HISAMITSU PHARMACEUTICAL CO.,INC. [4530.T]

TOKYO, Feb 3 (Reuters) - Taiyo Kobo Co., Ltd. announced today that it has submitted an amended tender offer filing to the Commissioner of the Tokyo Regional Finance Bureau regarding its public tender offer for Hisamitsu Pharmaceutical Co., Inc.'s common shares, subscription rights, and depositary receipts. The original tender offer was initially filed on January 7, 2026, and subsequently corrected on January 14, 2026.

Taiyo Kobo's decision to initiate this tender offer stems from its intention to acquire Hisamitsu Pharmaceutical's securities through a public tender offer process as stipulated under Japan’s Financial Instruments and Exchange Act. The company made this move after the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States concluded without any objections.

The amendment to the tender offer filing is necessitated by certain corrections needed in the initial announcement released on January 7, 2026. These changes do not alter the terms defined under Article 27, Paragraph 3, Item 1 of the Financial Instruments and Exchange Act, which governs conditions related to the tender offer. Specifically, the revised document clarifies the circumstances under which Taiyo Kobo might withdraw or modify the tender offer, including situations where significant legal issues arise during the tender period or if regulatory approvals are not obtained within the specified timeframe.

In addition to these procedural updates, Taiyo Kobo will ensure transparency throughout the tender process by making necessary announcements via electronic bulletin boards and print media such as the Nikkei newspaper, adhering strictly to guidelines set forth by the Ministry of Finance Order No. 38 issued in 1990. This ensures all stakeholders receive timely information about any potential modifications to the tender offer conditions.

AI-translated content. 🟢 Confidence: High See terms • Original filing